Pharos IBio Co Ltd
388870
Company Profile
Business description
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.
Contact
427beon-gil, Dongan-gu
1407 and 1408, 38, Heungan-daero, Seongji Star With
Gyeonggi-do, Gwanyang-dong
Anyang-si
KORT: +82 313456170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,028.30 | 98.90 | -1.08% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,395.16 | 101.39 | -0.40% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,945.68 | 364.81 | -0.86% |
| NZX 50 Index | 13,054.58 | 78.58 | -0.60% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,757.70 | 101.30 | -1.14% |
| SSE Composite Index | 3,820.98 | 37.15 | -0.96% |